Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nanologica AB ( (SE:NICA) ) just unveiled an update.
Nanologica AB, headquartered in Södertälje and listed on Nasdaq Stockholm’s Main Market, focuses on tools and contract manufacturing for peptide-based pharmaceuticals, targeting efficiency and cost reductions for drug makers. Through its Nanologica and Syntagon units, the group serves a global market for diabetes and obesity therapies and broader small-molecule and peptide development.
During March, Nanologica’s number of registered shares increased by 31,603,780 to 119,973,600 as part of previously approved directed share issues, raising the company’s share capital from SEK 4,506,860.82 to SEK 6,118,653.60. The capital increase, with a further 2,600,000 shares still to be registered in connection with a rights issue, strengthens the company’s financial base and expands its shareholder structure ahead of continued growth efforts.
The most recent analyst rating on (SE:NICA) stock is a Sell with a SEK0.32 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.
More about Nanologica AB
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells advanced consumables used by pharmaceutical manufacturers, particularly for the purification of peptide drugs such as insulin and GLP-1 analogues. Operating in a growing global niche driven by rising demand for diabetes and obesity treatments, the group also includes Syntagon, a contract manufacturer specializing in small molecules and peptides, with strong capabilities in purification and analysis of complex pharmaceutical compounds.
Average Trading Volume: 184,302
Technical Sentiment Signal: Sell
Current Market Cap: SEK38.43M
Find detailed analytics on NICA stock on TipRanks’ Stock Analysis page.